Univariate analysis of risk factors associated with MC-TA-TMA using Cho and Jodele criteria in patients receiving allogeneic or autologous HCT
| Factors . | Cho criteria . | Jodele criteria . | ||
|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Age at transplant, y | 1.01 (0.97-1.1) | .5 | 1.006 (0.97-1.04) | .7 |
| Sex | ||||
| Female | 1 | 1 | ||
| Male | 1.3 (0.7-2.3) | .4 | 0.7 (0.5-1.2) | .2 |
| Number of HCTs | ||||
| None or 1 HCT | 1 | 1 | ||
| ≥2 HCTs | 3.5 (1.7-7.0) | .0005 | 2.1 (1.1-4.1) | .03 |
| HCT indication | .1 | .02 | ||
| Solid tumor | 1 | 1 | ||
| Hematologic malignancy | 2.4 (1.1-5.2) | .03 | 2.5 (1.3-4.8) | .008 |
| Immunodeficiency | 1.8 (0.7-4.3) | .2 | 2.3 (1.1-4.8) | .02 |
| Heme | 1.3 (0.5-3.6) | .6 | 2.1 (0.9-4.7) | .07 |
| Metabolic/neurodegenerative | 0.2 (0.009-3.4) | .2 | 0.5 (0.1-2.3) | .4 |
| Transplant type | ||||
| Autologous | 1 | 1 | ||
| Allogeneic | 2.2 (1.1-4.2) | .02 | 3.0 (1.7-5.1) | .0001 |
| Cell source† | .1 | .003 | ||
| Bone marrow | 1 | 1 | ||
| Peripheral blood | 2.7 (0.6-12.7) | .2 | 1.1 (0.2-5.1) | .9 |
| Umbilical cord | 2.5 (0.9-7.1) | .07 | 4.8 (1.5-15.3) | .08 |
| Related donor† | ||||
| Yes | 1 | 1 | ||
| No | 1.7 (0.9-3.4) | .1 | 2.1 (1.2-3.7) | .01 |
| HLA match†,‡ | .03 | .004 | ||
| 10/10 | 1 | 1 | ||
| 9/10 | 2.2 (0.97-4.9) | .06 | 1.4 (0.6-2.8) | .4 |
| ≤8/10 | 2.7 (1.1-6.3) | .03 | 4.4 (1.8-10.7) | .0009 |
| Conditioning† | .3 | .4 | ||
| Nonmyeloablative | 1 | 1 | ||
| Myeloablative | 1.5 (0.4-5.5) | .6 | 0.5 (0.2-1.4) | .2 |
| Reduced intensity | 0.8 (0.2-3.5) | .8 | 0.5 (0.2-1.6) | .3 |
| Active aGVHD† | ||||
| Grade 1/2, no aGVHD, or nonactive grade 3/4 aGVHD | 1 | 1 | ||
| Active grade 3/4 aGVHD | 6.9 (2.1-22.2) | .001 | 19.7 (2.5-154.9) | .005 |
| VOD | ||||
| No | 1 | 1 | ||
| Yes | 2.0 (0.6-7.0) | .3 | 2.6 (0.8-8.4) | .1 |
| Any active infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 137 (33.8-559.4) | <.0001 | 50 (9.3-271.1) | <.0001 |
| Active bacterial infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 168.5 (9.1 to >999.9) | .0006 | 56.3 (3.1 to >999.9) | .007 |
| Active viral infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 105.3 (26.1-424.3) | <.0001 | 43.5 (8.0-236.4) | <.0001 |
| Active fungal infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 38.7 (1.6-939.9) | .02 | 15.2 (0.6-366.8) | .09 |
| Factors . | Cho criteria . | Jodele criteria . | ||
|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Age at transplant, y | 1.01 (0.97-1.1) | .5 | 1.006 (0.97-1.04) | .7 |
| Sex | ||||
| Female | 1 | 1 | ||
| Male | 1.3 (0.7-2.3) | .4 | 0.7 (0.5-1.2) | .2 |
| Number of HCTs | ||||
| None or 1 HCT | 1 | 1 | ||
| ≥2 HCTs | 3.5 (1.7-7.0) | .0005 | 2.1 (1.1-4.1) | .03 |
| HCT indication | .1 | .02 | ||
| Solid tumor | 1 | 1 | ||
| Hematologic malignancy | 2.4 (1.1-5.2) | .03 | 2.5 (1.3-4.8) | .008 |
| Immunodeficiency | 1.8 (0.7-4.3) | .2 | 2.3 (1.1-4.8) | .02 |
| Heme | 1.3 (0.5-3.6) | .6 | 2.1 (0.9-4.7) | .07 |
| Metabolic/neurodegenerative | 0.2 (0.009-3.4) | .2 | 0.5 (0.1-2.3) | .4 |
| Transplant type | ||||
| Autologous | 1 | 1 | ||
| Allogeneic | 2.2 (1.1-4.2) | .02 | 3.0 (1.7-5.1) | .0001 |
| Cell source† | .1 | .003 | ||
| Bone marrow | 1 | 1 | ||
| Peripheral blood | 2.7 (0.6-12.7) | .2 | 1.1 (0.2-5.1) | .9 |
| Umbilical cord | 2.5 (0.9-7.1) | .07 | 4.8 (1.5-15.3) | .08 |
| Related donor† | ||||
| Yes | 1 | 1 | ||
| No | 1.7 (0.9-3.4) | .1 | 2.1 (1.2-3.7) | .01 |
| HLA match†,‡ | .03 | .004 | ||
| 10/10 | 1 | 1 | ||
| 9/10 | 2.2 (0.97-4.9) | .06 | 1.4 (0.6-2.8) | .4 |
| ≤8/10 | 2.7 (1.1-6.3) | .03 | 4.4 (1.8-10.7) | .0009 |
| Conditioning† | .3 | .4 | ||
| Nonmyeloablative | 1 | 1 | ||
| Myeloablative | 1.5 (0.4-5.5) | .6 | 0.5 (0.2-1.4) | .2 |
| Reduced intensity | 0.8 (0.2-3.5) | .8 | 0.5 (0.2-1.6) | .3 |
| Active aGVHD† | ||||
| Grade 1/2, no aGVHD, or nonactive grade 3/4 aGVHD | 1 | 1 | ||
| Active grade 3/4 aGVHD | 6.9 (2.1-22.2) | .001 | 19.7 (2.5-154.9) | .005 |
| VOD | ||||
| No | 1 | 1 | ||
| Yes | 2.0 (0.6-7.0) | .3 | 2.6 (0.8-8.4) | .1 |
| Any active infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 137 (33.8-559.4) | <.0001 | 50 (9.3-271.1) | <.0001 |
| Active bacterial infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 168.5 (9.1 to >999.9) | .0006 | 56.3 (3.1 to >999.9) | .007 |
| Active viral infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 105.3 (26.1-424.3) | <.0001 | 43.5 (8.0-236.4) | <.0001 |
| Active fungal infection*,§ | ||||
| No | 1 | 1 | ||
| Yes | 38.7 (1.6-939.9) | .02 | 15.2 (0.6-366.8) | .09 |
Variables were analyzed using a univariate logistic regression model, age was analyzed as a continuous variable, and risk reported is for every year older at HCT. Bold P values denote characteristics significantly associated with MC-TA-TMA. For HCT indication, cell source, HLA match, conditioning, and aGVHD, odds ratios (OR) were compared to the reference group (OR = 1); the P value denotes characteristics significantly associated with MC-TA-TMA compared to the reference group.
CI, confidence interval; VOD, veno-occlusive disease.
Firth’s penalized maximum likelihood estimation was performed for active infection variables.
Allogeneic HCT only.
Bone marrow transplant and peripheral blood stem cell source only.
Multiple infections can occur simultaneously.